Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/22
Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual MeetingGlobeNewsWire • 03/28/22
Atea Pharmaceuticals, Inc. (AVIR) Surges 7.4%: Is This an Indication of Further Gains?Zacks Investment Research • 03/21/22
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Zoom Reports Slowing Growth, but This Stock Is Monday's Real After-Hours WinnerThe Motley Fool • 03/01/22
Dow Jones Newswires: Atea Pharma stock jumps as earnings rise, potential COVID-19 therapy advancesMarket Watch • 02/28/22
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/22
Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atea Pharmaceuticals, Inc. - AVIRNewsfile Corp • 02/03/22
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) InvestigationBusiness Wire • 01/12/22
Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19GlobeNewsWire • 12/14/21
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/12/21
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial ResultsGlobeNewsWire • 11/11/21
Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021GlobeNewsWire • 11/04/21